Rocket Pharmaceuticals Inc’s filing revealed that its insider White Mark Andrew unloaded Company’s shares for reported $0.31 million on Apr 08 ’24. In the deal valued at $24.64 per share,12,532 shares were sold. As a result of this transaction, White Mark Andrew now holds 75,226 shares worth roughly $1.81 million.
Then, Makker Gotham sold 274,000 shares, generating $7,790,943 in total proceeds. Upon selling the shares at $28.43, the Director now owns 365,912 shares.
Before that, Militello John sold 2,490 shares. Rocket Pharmaceuticals Inc shares valued at $69,979 were divested by the insider at a price of $28.10 per share. As a result of the transaction, Militello John now holds 55,239 shares, worth roughly $1.33 million.
Goldman initiated its Rocket Pharmaceuticals Inc [RCKT] rating to a Neutral in a research note published on April 02, 2024; the price target was $39. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in late October with a ‘”an Overweight”‘ rating. Morgan Stanley began covering RCKT with “an Overweight” recommendation on February 01, 2023. Canaccord Genuity started covering the stock on November 08, 2022. It rated RCKT as “a Buy”.
Price Performance Review of RCKT
On Monday, Rocket Pharmaceuticals Inc [NASDAQ:RCKT] saw its stock fall -0.74% to $24.01. Over the last five days, the stock has lost -1.56%. Rocket Pharmaceuticals Inc shares have fallen nearly -19.89% since the year began. Nevertheless, the stocks have risen 30.28% over the past one year. While a 52-week high of $32.53 was reached on 02/27/24, a 52-week low of $14.89 was recorded on 04/15/24. SMA at 50 days reached $27.66, while 200 days put it at $22.92. A total of 0.58 million shares were traded, compared to the trading of 0.68 million shares in the previous session.
Levels Of Support And Resistance For RCKT Stock
The 24-hour chart illustrates a support level at 23.69, which if violated will result in even more drops to 23.36. On the upside, there is a resistance level at 24.42. A further resistance level may holdings at 24.82. The Relative Strength Index (RSI) on the 14-day chart is 36.18, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.95, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.19%. Stochastics %K at 15.00% indicates the stock is a buying.
The most recent change occurred on November 01, 2022 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $35 price target.
